CleanCap® Reagent AU is designed for the co-transcriptional capping of mRNA to produce an mRNA with naturally occurring Cap 1. CleanCap Reagent AU was specifically designed for self-replicating RNAs based on the genomes of positive sense strand RNA viruses such as Venezuelan equine encephalitis virus (VEEV), Semliki forest virus (SFV), and Sindbis virus (SIN).
The positive sense strand genomes of these viruses start with a 5’ AU structure. Cap 1 mRNAs have superior in vivo activity compared to Cap 0 mRNA produced by legacy co-transcriptional capping methods like anti-reverse cap analog (ARCA).
PLEASE NOTE: CleanCap Reagent AU requires an AU initiator. To learn more, please review the Product Insert below.
Our CleanCap reagents are available in “Research Use” grade as well as GMP-grade “For Further Processing.” GMP product is manufactured in accordance with ISO 9001:2015 and Quality Standards as defined in a GMP Quality Agreement, and must be further processed by the client.
To learn more visit: https://www.trilinkbiotech.com/gmp-reagents
|Purity||≥95% by AX-HPLC|
|Extinction Coefficient||33,400 Lmol-1cm-1 at 258 nm|
|Molecular Formula||C31H42N12O25P4 (free acid)|
|Molecular Weight||1106.6 g/mole (free acid)|
|Recommended Storage||-20°C or below|
|Other Name(s)||CleanCap® AU for Self-Amplifying mRNA, CleanCap® Reagent AU for co-transcriptional capping of mRNA, m7G(5')ppp(5')(2'OMeA)pU|
|Application||CRISPR, In vitro Transcription, Recombinases, TALENS, Transposases, Vaccine Development, Zinc Finger Nucleases|
|Base Analog(s)||Adenosine, Uridine|
|Nucleotide Category||Cap analogs|
CleanCap For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at trilinkbiotech.com/cleancap-research-license. Patent or patent pending,see trilinkbiotech.com/legal-notices.
Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission of Seller. No license under any patent or other intellectual property right of Seller or its licensors is granted or implied by the purchase unless otherwise provided in writing.
TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.
Pollock, KM;Cheeseman, HM;Szubert, AJ;Libri, V;Boffito, M;Owen, D;Bern, H;O'Hara, J;McFarlane, LR;Lemm, NM;McKay, PF;Rampling, T;Yim, YTN;Milinkovic, A;Kingsley, C;Cole, T;Fagerbrink, S;Aban, M;Tanaka, M;Mehdipour, S;Robbins, A;Budd, W;Faust, SN;Hassanin, H;Cosgrove, CA;Winston, A;Fidler, S;Dunn, DT;McCormack, S;Shattock, RJ;COVAC1 study Group, ; . Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial
Minnaert, AK;Vanluchene, H;Verbeke, R;Lentacker, I;De Smedt, SC;Raemdonck, K;Sanders, NN;Remaut, K; . Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: getting the message across